RoslinCT, Lykan Biosciences Add Six cGMP Suites to Massachusetts Facility
Expansion expected to increase global capacity by 75%.
RoslinCT and Lykan Biosciences, two contract development and manufacturing organizations (CDMOs), are adding six new cGMP processing suites to their facility in Hopkinton, Mass. The new sites bring the companies’ total to 22 overall, with 14 at the aforementioned location and another eight in Edinburgh, UK.
Ranging from 105 to 525 square feet, the new processing suites are designed to meet both US and EU regulatory requirements for clinical and commercial manufacturing. As part of the increase, an automated processing room is included and will reportedly be capable of accommodating a range of manufacturing platforms as well as allogeneic and autologous-based products.
“With this expansion, we will increase our capacity by 75% enabling us to meet the needs of a greater number of projects and their respective volume requirements,” says Patrick Lucy, president and CEO of Lykan Biosciences.
Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration
May 8th 2025The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
